ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2

ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2

Ovarian cancer is one of the deadliest gynecological malignancies in women. Chemoresistance has been a major obstacle for ovarian cancer treatment. Zinc finger E-box-binding homeobox 1 (ZEB1) is an important regulator of tumor development in various types of cancer. Abnormal expression of SLC3A2 (CD...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chemotherapy (Basel) 2018-01, Vol.63 (5), p.262-271
Hauptverfasser: Cui, Yajie, Qin, Li, Tian, Defu, Wang, Ting, Fan, Lijing, Zhang, Peilian, Wang, Zhongqi
Format: Artikel
Sprache:eng
Schlagworte:
Anticancer Section / Original Paper
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 271
container_issue 5
container_start_page 262
container_title Chemotherapy (Basel)
container_volume 63
creator Cui, Yajie
Qin, Li
Tian, Defu
Wang, Ting
Fan, Lijing
Zhang, Peilian
Wang, Zhongqi
description Ovarian cancer is one of the deadliest gynecological malignancies in women. Chemoresistance has been a major obstacle for ovarian cancer treatment. Zinc finger E-box-binding homeobox 1 (ZEB1) is an important regulator of tumor development in various types of cancer. Abnormal expression of SLC3A2 (CD98hc), a type 2 transmembrane cell surface molecule, has been described in several cancers. This study was designed to investigate the role of ZEB1 and SLC3A2 in the chemoresistance to cisplatin in ovarian cancer cells. We found that ZEB1 was increased in cisplatin-resistant SKOV3/DPP cells. Downregulation of ZEB1 significantly decreased cell viability in response to cisplatin, increased cis­platin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin. In addition, downregulation of ZEB1 decreased the volume and weight of implanted tumors. SLC3A2 was decreased in cisplatin-resistant SKOV3/DPP cells. Upregulation of SLC3A2 significantly decreased cell viability in response to cisplatin, increased cisplatin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin. Moreover, upregulation of SLC3A2 decreased the volume and weight of implanted tumors. Downregulation of ZEB1 resulted in a significant increase of SLC3A2 expression. Moreover, downregulation of SLC3A2 significantly inhibited ZEB1 knockdown-mediated inhibition of cisplatin-resistance. ZEB1-mediated regulation of SLC3A2 was involved in the chemoresistance to cisplatin in ovarian cancer cells. Overall, we provide new insights into the mechanism of chemoresistance to cisplatin in ovarian cancer cells. ZEB1/SLC3A2 may be promising therapeutic targets for enhancement of the sensitivity of ovarian cancer cells to cisplatin-mediated chemotherapy.
doi_str_mv 10.1159/000493864
format Article
fullrecord <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_proquest_miscellaneous_2138641518</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2138641518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c334t-dbe60d1d8b70e2cdb9130a2424a18f1cf42878f50e25a895a7b93c5cde2fabd63</originalsourceid><addsrcrecordid>eNptkM1Lw0AQxRdRbK0evIsseNFDdCe7SXaPNVQrFCpUQbyEzWZTo82Hu4nQ_94tqTkJA8PM-81jeAidA7kFCMQdIYQJykN2gMbAfPBEJNghGru98CgE0QidWPvpRhpSOEYjShiHiAdj9PY-uwf8bOqybrXF8Ycua6NtYVtZKY3bGseFbTayLSrsavkjTSErHO9Ug2O92VicbvGqaxp3ZotqjVeLmE79U3SUy43VZ_s-Qa8Ps5d47i2Wj0_xdOEpSlnrZakOSQYZTyOifZWlAiiRPvOZBJ6DypnPI54HTgwkF4GMUkFVoDLt5zLNQjpB171vY-rvTts2KQur3F-y0nVnEx92wUAA3KE3PapMba3RedKYopRmmwBJdkEmQ5COvdzbdmmps4H8S84BFz3wJc1amwEY7q_-leP5rCeSJsvpL_E3gX4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2138641518</pqid></control><display><type>article</type><title>ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2</title><source>Karger Journals</source><creator>Cui, Yajie ; Qin, Li ; Tian, Defu ; Wang, Ting ; Fan, Lijing ; Zhang, Peilian ; Wang, Zhongqi</creator><creatorcontrib>Cui, Yajie ; Qin, Li ; Tian, Defu ; Wang, Ting ; Fan, Lijing ; Zhang, Peilian ; Wang, Zhongqi</creatorcontrib><description>Ovarian cancer is one of the deadliest gynecological malignancies in women. Chemoresistance has been a major obstacle for ovarian cancer treatment. Zinc finger E-box-binding homeobox 1 (ZEB1) is an important regulator of tumor development in various types of cancer. Abnormal expression of SLC3A2 (CD98hc), a type 2 transmembrane cell surface molecule, has been described in several cancers. This study was designed to investigate the role of ZEB1 and SLC3A2 in the chemoresistance to cisplatin in ovarian cancer cells. We found that ZEB1 was increased in cisplatin-resistant SKOV3/DPP cells. Downregulation of ZEB1 significantly decreased cell viability in response to cisplatin, increased cis­platin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin. In addition, downregulation of ZEB1 decreased the volume and weight of implanted tumors. SLC3A2 was decreased in cisplatin-resistant SKOV3/DPP cells. Upregulation of SLC3A2 significantly decreased cell viability in response to cisplatin, increased cisplatin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin. Moreover, upregulation of SLC3A2 decreased the volume and weight of implanted tumors. Downregulation of ZEB1 resulted in a significant increase of SLC3A2 expression. Moreover, downregulation of SLC3A2 significantly inhibited ZEB1 knockdown-mediated inhibition of cisplatin-resistance. ZEB1-mediated regulation of SLC3A2 was involved in the chemoresistance to cisplatin in ovarian cancer cells. Overall, we provide new insights into the mechanism of chemoresistance to cisplatin in ovarian cancer cells. ZEB1/SLC3A2 may be promising therapeutic targets for enhancement of the sensitivity of ovarian cancer cells to cisplatin-mediated chemotherapy.</description><identifier>ISSN: 0009-3157</identifier><identifier>EISSN: 1421-9794</identifier><identifier>DOI: 10.1159/000493864</identifier><identifier>PMID: 30481785</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Anticancer Section / Original Paper</subject><ispartof>Chemotherapy (Basel), 2018-01, Vol.63 (5), p.262-271</ispartof><rights>2018 S. Karger AG, Basel</rights><rights>2018 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c334t-dbe60d1d8b70e2cdb9130a2424a18f1cf42878f50e25a895a7b93c5cde2fabd63</citedby><cites>FETCH-LOGICAL-c334t-dbe60d1d8b70e2cdb9130a2424a18f1cf42878f50e25a895a7b93c5cde2fabd63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,2430,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30481785$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cui, Yajie</creatorcontrib><creatorcontrib>Qin, Li</creatorcontrib><creatorcontrib>Tian, Defu</creatorcontrib><creatorcontrib>Wang, Ting</creatorcontrib><creatorcontrib>Fan, Lijing</creatorcontrib><creatorcontrib>Zhang, Peilian</creatorcontrib><creatorcontrib>Wang, Zhongqi</creatorcontrib><title>ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2</title><title>Chemotherapy (Basel)</title><addtitle>Chemotherapy</addtitle><description>Ovarian cancer is one of the deadliest gynecological malignancies in women. Chemoresistance has been a major obstacle for ovarian cancer treatment. Zinc finger E-box-binding homeobox 1 (ZEB1) is an important regulator of tumor development in various types of cancer. Abnormal expression of SLC3A2 (CD98hc), a type 2 transmembrane cell surface molecule, has been described in several cancers. This study was designed to investigate the role of ZEB1 and SLC3A2 in the chemoresistance to cisplatin in ovarian cancer cells. We found that ZEB1 was increased in cisplatin-resistant SKOV3/DPP cells. Downregulation of ZEB1 significantly decreased cell viability in response to cisplatin, increased cis­platin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin. In addition, downregulation of ZEB1 decreased the volume and weight of implanted tumors. SLC3A2 was decreased in cisplatin-resistant SKOV3/DPP cells. Upregulation of SLC3A2 significantly decreased cell viability in response to cisplatin, increased cisplatin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin. Moreover, upregulation of SLC3A2 decreased the volume and weight of implanted tumors. Downregulation of ZEB1 resulted in a significant increase of SLC3A2 expression. Moreover, downregulation of SLC3A2 significantly inhibited ZEB1 knockdown-mediated inhibition of cisplatin-resistance. ZEB1-mediated regulation of SLC3A2 was involved in the chemoresistance to cisplatin in ovarian cancer cells. Overall, we provide new insights into the mechanism of chemoresistance to cisplatin in ovarian cancer cells. ZEB1/SLC3A2 may be promising therapeutic targets for enhancement of the sensitivity of ovarian cancer cells to cisplatin-mediated chemotherapy.</description><subject>Anticancer Section / Original Paper</subject><issn>0009-3157</issn><issn>1421-9794</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNptkM1Lw0AQxRdRbK0evIsseNFDdCe7SXaPNVQrFCpUQbyEzWZTo82Hu4nQ_94tqTkJA8PM-81jeAidA7kFCMQdIYQJykN2gMbAfPBEJNghGru98CgE0QidWPvpRhpSOEYjShiHiAdj9PY-uwf8bOqybrXF8Ycua6NtYVtZKY3bGseFbTayLSrsavkjTSErHO9Ug2O92VicbvGqaxp3ZotqjVeLmE79U3SUy43VZ_s-Qa8Ps5d47i2Wj0_xdOEpSlnrZakOSQYZTyOifZWlAiiRPvOZBJ6DypnPI54HTgwkF4GMUkFVoDLt5zLNQjpB171vY-rvTts2KQur3F-y0nVnEx92wUAA3KE3PapMba3RedKYopRmmwBJdkEmQ5COvdzbdmmps4H8S84BFz3wJc1amwEY7q_-leP5rCeSJsvpL_E3gX4</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Cui, Yajie</creator><creator>Qin, Li</creator><creator>Tian, Defu</creator><creator>Wang, Ting</creator><creator>Fan, Lijing</creator><creator>Zhang, Peilian</creator><creator>Wang, Zhongqi</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180101</creationdate><title>ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2</title><author>Cui, Yajie ; Qin, Li ; Tian, Defu ; Wang, Ting ; Fan, Lijing ; Zhang, Peilian ; Wang, Zhongqi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c334t-dbe60d1d8b70e2cdb9130a2424a18f1cf42878f50e25a895a7b93c5cde2fabd63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anticancer Section / Original Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cui, Yajie</creatorcontrib><creatorcontrib>Qin, Li</creatorcontrib><creatorcontrib>Tian, Defu</creatorcontrib><creatorcontrib>Wang, Ting</creatorcontrib><creatorcontrib>Fan, Lijing</creatorcontrib><creatorcontrib>Zhang, Peilian</creatorcontrib><creatorcontrib>Wang, Zhongqi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chemotherapy (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cui, Yajie</au><au>Qin, Li</au><au>Tian, Defu</au><au>Wang, Ting</au><au>Fan, Lijing</au><au>Zhang, Peilian</au><au>Wang, Zhongqi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2</atitle><jtitle>Chemotherapy (Basel)</jtitle><addtitle>Chemotherapy</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>63</volume><issue>5</issue><spage>262</spage><epage>271</epage><pages>262-271</pages><issn>0009-3157</issn><eissn>1421-9794</eissn><abstract>Ovarian cancer is one of the deadliest gynecological malignancies in women. Chemoresistance has been a major obstacle for ovarian cancer treatment. Zinc finger E-box-binding homeobox 1 (ZEB1) is an important regulator of tumor development in various types of cancer. Abnormal expression of SLC3A2 (CD98hc), a type 2 transmembrane cell surface molecule, has been described in several cancers. This study was designed to investigate the role of ZEB1 and SLC3A2 in the chemoresistance to cisplatin in ovarian cancer cells. We found that ZEB1 was increased in cisplatin-resistant SKOV3/DPP cells. Downregulation of ZEB1 significantly decreased cell viability in response to cisplatin, increased cis­platin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin. In addition, downregulation of ZEB1 decreased the volume and weight of implanted tumors. SLC3A2 was decreased in cisplatin-resistant SKOV3/DPP cells. Upregulation of SLC3A2 significantly decreased cell viability in response to cisplatin, increased cisplatin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin. Moreover, upregulation of SLC3A2 decreased the volume and weight of implanted tumors. Downregulation of ZEB1 resulted in a significant increase of SLC3A2 expression. Moreover, downregulation of SLC3A2 significantly inhibited ZEB1 knockdown-mediated inhibition of cisplatin-resistance. ZEB1-mediated regulation of SLC3A2 was involved in the chemoresistance to cisplatin in ovarian cancer cells. Overall, we provide new insights into the mechanism of chemoresistance to cisplatin in ovarian cancer cells. ZEB1/SLC3A2 may be promising therapeutic targets for enhancement of the sensitivity of ovarian cancer cells to cisplatin-mediated chemotherapy.</abstract><cop>Basel, Switzerland</cop><pmid>30481785</pmid><doi>10.1159/000493864</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-3157
ispartof Chemotherapy (Basel), 2018-01, Vol.63 (5), p.262-271
issn 0009-3157
1421-9794
language eng
recordid cdi_proquest_miscellaneous_2138641518
source Karger Journals
subjects Anticancer Section / Original Paper
title ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T02%3A34%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ZEB1%20Promotes%20Chemoresistance%20to%20Cisplatin%20in%20Ovarian%20Cancer%20Cells%20by%20Suppressing%20SLC3A2&rft.jtitle=Chemotherapy%20(Basel)&rft.au=Cui,%20Yajie&rft.date=2018-01-01&rft.volume=63&rft.issue=5&rft.spage=262&rft.epage=271&rft.pages=262-271&rft.issn=0009-3157&rft.eissn=1421-9794&rft_id=info:doi/10.1159/000493864&rft_dat=%3Cproquest_karge%3E2138641518%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2138641518&rft_id=info:pmid/30481785&rfr_iscdi=true